Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00433953 · ClinicalTrials.gov registry record · Phase 1

Genetic Drug Study of Mycophenolic Acid (CellCept) in Pediatric Kidney Transplant Patients

A Phase 1 study, sponsored by Children's Hospital Medical Center, Cincinnati.

Terminated
Registry status
Phase 1
Development phase
44
Enrollment target

NCT00433953 is a Phase 1 study that was terminated before completion, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 44 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00433953, a Phase 1 study, was terminated before completion, sponsored by Children's Hospital Medical Center, Cincinnati.

TERMINATED
Registry status
Phase 1
Development phase
44 participants
Enrollment target

Study Summary

The purpose of this study is to determine how genes influence the response to mycophenolate mofetil (CellCept) in children who have had a kidney transplant. The study will look at how differences in some genes effect blood levels of mycophenolate mofetil over time in children, how often side effects occur and the way that children respond to mycophenolate mofetil. The results may lead to better dosing based on individual needs.

Interventions

  • BEHAVIORAL Dietary Monitoring
  • PROCEDURE Blood Sampling
  • BEHAVIORAL Drug Diary
  • DRUG Mycophenolate Mofetil (CellCept)

Trial Details

FieldValue
Enrollment Target 44 participants
Start Date 2007-02
Est. Completion 2010-02
Phase Phase 1

What the Registry Record Tells You About NCT00433953

The ClinicalTrials.gov registry entry for NCT00433953 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Hospital Medical Center, Cincinnati, which has 571 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 4 interventions - of which Dietary Monitoring is the first listed.

NCT00433953 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00433953 about?

NCT00433953 is a clinical study titled "Genetic Drug Study of Mycophenolic Acid (CellCept) in Pediatric Kidney Transplant Patients". The purpose of this study is to determine how genes influence the response to mycophenolate mofetil (CellCept) in children who have had a kidney transplant. The study will look at how differences in some genes effect blood levels of mycophenolate mofetil over time in children, how often side effects...

What is the current status of trial NCT00433953?

This trial is currently terminated. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2007-02. Estimated completion is 2010-02.

What interventions are being tested in trial NCT00433953?

The interventions under investigation include: Dietary Monitoring (BEHAVIORAL), Blood Sampling (PROCEDURE), Drug Diary (BEHAVIORAL), Mycophenolate Mofetil (CellCept) (DRUG).

Who is sponsoring clinical trial NCT00433953?

This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.